← Human Trials & Peer-Reviewed Studies
Effects of nicotine patches on early and late attentional bias to smoking cues: We may know less than we think.
Plain-language guide to PMID 38330343 (2024): randomized controlled trial of Therapeutic nicotine (patch, non-peptide).
Key Facts
- PMID
- 38330343
- Journal
- Experimental and clinical psychopharmacology
- Year
- 2024
- Study type
- Randomized Controlled Trial
- Authors
- Stone BM et al. (4 authors)
- DOI
- 10.1037/pha0000707
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.
To assess the reliability of this failure and to address the duration and salience of AB in smokers versus never-smokers, the researchers used a longer-than-typical (i.e., 3,000 ms) smoking cue-presentation time in a placebo-controlled trial of smokers and never-smokers.
The researchers aimed to assess whether a nicotine patch (i.e., active vs. placebo) attenuates continuously assessed eye gaze-measured AB to smoking cues across 3,000 ms in 32 habitual, overnight-deprived smokers and smoker-nonsmoker differences compared to 32 never-smokers.
The researchers presented a series of picture pairs (i.e., one smoking-related and one affectively neutral control picture) simultaneously to assess AB.
Why It Was Studied
The habitual smokers were 12-18 hr nicotine-deprived during both sessions.
Who Took Part
The age groups tagged for this paper are young adults and adults, both men and women.
How the Study Was Run
The design is described as randomized and placebo-controlled.
Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
The comparison arm used a placebo, so changes seen with Therapeutic nicotine (patch, non-peptide) could be set against what happens without it.
What Was Measured
The subject headings attached to it are Cues, Attentional Bias, Tobacco Use Cessation Devices, Nicotine, Smoking and Smoking Cessation.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).
The publication is from 2024 (Experimental and clinical psychopharmacology), a journal based in United States.
More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.
Our Notes on the Compound
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.